It was seen that 36% patients with measurable PIK3CA‐mutated advanced BC responded to alpelisib combination whereas ORR was 16% in the placebo group (P = 0.0002).79 Further data on other endpoints from this trial is awaited and will help strengthen treatment strategy based on patient's tumor genomic profile (Table 3). Here, PIK3CA is linked to breast cancer.